LTRN
FDA meeting: the “can we tweak this?” edition
Lantern Pharma is heading into a Type C meeting with the FDA in mid-May to discuss proposed changes to its Phase 2 HARMONIC trial for LP-300 in non-small cell lung cancer. Translation: the company wants to adjust the recipe before it keeps cooking.
What’s on the table?
The proposed protocol changes are pretty specific, which is usually how biotech tries to turn promising signals into a cleaner trial story:
- restrict future enrollment to EGFR Exon 21 L858R patients
- switch to a Phase 2 single-arm Simon two-stage design
- increase LP-300 treatment from six cycles to eight
That’s a lot of trial gardening, but the point is simple: Lantern wants a more focused study that may better highlight whether LP-300 is doing the heavy lifting.
Why investors should care
The company says patients with the L858R mutation who finished six cycles of LP-300 had a median progression-free survival of 8.9 months, and it also flagged comparable safety across people who got four or six cycles. That’s the kind of early readout that can make investors squint and ask, “Okay, but is this the start of something bigger or just biotech being biotech?”
Big picture
If the FDA is open to the amendments, Lantern could come out with a cleaner, more targeted development path. If not, the stock may get stuck in the usual clinical-trial waiting room, where time moves slower than a pharmacy line on a Monday morning.